1. Home
  2. WEAV vs GERN Comparison

WEAV vs GERN Comparison

Compare WEAV & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WEAV
  • GERN
  • Stock Information
  • Founded
  • WEAV 2011
  • GERN 1990
  • Country
  • WEAV United States
  • GERN United States
  • Employees
  • WEAV N/A
  • GERN N/A
  • Industry
  • WEAV EDP Services
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • WEAV Technology
  • GERN Health Care
  • Exchange
  • WEAV Nasdaq
  • GERN Nasdaq
  • Market Cap
  • WEAV 837.7M
  • GERN 853.5M
  • IPO Year
  • WEAV 2021
  • GERN 1996
  • Fundamental
  • Price
  • WEAV $9.71
  • GERN $1.56
  • Analyst Decision
  • WEAV Strong Buy
  • GERN Buy
  • Analyst Count
  • WEAV 5
  • GERN 9
  • Target Price
  • WEAV $16.10
  • GERN $5.13
  • AVG Volume (30 Days)
  • WEAV 808.7K
  • GERN 12.2M
  • Earning Date
  • WEAV 07-30-2025
  • GERN 05-07-2025
  • Dividend Yield
  • WEAV N/A
  • GERN N/A
  • EPS Growth
  • WEAV N/A
  • GERN N/A
  • EPS
  • WEAV N/A
  • GERN N/A
  • Revenue
  • WEAV $212,950,000.00
  • GERN $116,293,000.00
  • Revenue This Year
  • WEAV $18.69
  • GERN $160.12
  • Revenue Next Year
  • WEAV $15.71
  • GERN $55.01
  • P/E Ratio
  • WEAV N/A
  • GERN N/A
  • Revenue Growth
  • WEAV 19.58
  • GERN 22264.04
  • 52 Week Low
  • WEAV $8.40
  • GERN $1.17
  • 52 Week High
  • WEAV $17.63
  • GERN $5.34
  • Technical
  • Relative Strength Index (RSI)
  • WEAV 44.31
  • GERN 58.61
  • Support Level
  • WEAV $9.29
  • GERN $1.39
  • Resistance Level
  • WEAV $9.70
  • GERN $1.60
  • Average True Range (ATR)
  • WEAV 0.31
  • GERN 0.12
  • MACD
  • WEAV -0.03
  • GERN 0.03
  • Stochastic Oscillator
  • WEAV 26.25
  • GERN 90.24

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, it enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue primarily from subscription services.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: